Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma

Therapeutic Advances in Urology

Volumn 7, Issue 3, 2015, Pages 152-161

  Zanardi, Elisa ^a   Verzoni, Elena ^a   Grassi, Paolo ^a   Necchi, Andrea ^a   Giannatempo, Patrizia ^a   Raggi, Daniele ^a   de Braud, Filippo ^a   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

mTOR inhibitors; renal cell carcinoma; targeted therapies; temsirolimus

Indexed keywords

TEMSIROLIMUS;

ACNE; ADVANCED CANCER; ANEMIA; ANOREXIA; APHTHOUS STOMATITIS; ASTHENIA; CANCER PATIENT; CANCER PROGNOSIS; CHILL; COUGHING; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; MOUTH ULCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84930403925     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287215574457     Document Type: Review

References (35)

1. Atkins M. Hidalgo M. Stadler W. Logan T. Dutcher J. Hudes G. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–918.
2. Bellmunt J. Szczylik C. Feingold J. Strahs A. Berkenblit A. (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19: 1387–1392.
3. Bukowski R. Negrier S. Elson P. (2004) Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 10: 6310S–6314S.
4. Cheville J. Lohse C. Zincke H. Weaver A. Blute M. (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612–624.
5. Cohen H. McGovern F. (2005) Renal-cell carcinoma. N Engl J Med 353: 2477–2490.
6. Dolan P. (1997) Modeling valuations for EuroQol health states. Med Care 35: 1095–1108.
7. Duran I. Siu L. Oza A. Chung T. Sturgeon J. Townsley C. (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42: 1875–1880.
8. Dutcher J. de Souza P. McDermott D. Figlin R. Berkenblit A. Thiele A. (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26: 202–209.
9. Escudier B. Porta C. Schmidinger M. Algaba F. Patard J. Khoo V. (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25: iii49–iii56.
10. Figlin R. de Souza P. McDermott D. Dutcher J. Berkenblit A. Thiele A. (2009) Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 115: 3651–3660.
11. Fyfe G. Fisher R. Rosenberg S. Sznol M. Parkinson D. Louie A. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696.
12. Garcia J. Rini B. (2007) Recent progress in the management of advancedrenal cell carcinoma. CA Cancer J Clin 57: 112–125.
13. Gibbons J. (2006) CCI-779 Potentiates the inhibitory effect of the anti-angiogenesis drug interferon-alpha on the growth of a human renal cell carcinoma in nude mice: RPT-49843. Pearl River, NY: Wyeth Research.
14. Heng D. Xie W. Regan M. Warren M. Golshayan A. Sahi C. (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794–5799.
15. Hidalgo M. Buckner J. Erlichman C. Pollack M. Boni J. Dukart G. (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12: 5755–5763.
16. Hudes G. Carducci M. Tomczak P. Dutcher J. Figlin R. Kapoor A. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281.
17. Hudes G. (2009) Targeting mTOR in renal cell carcinoma. Cancer 115: 2313–2320.
18. Hutson T. Escudier B. Esteban E. Bjarnason G. Lim H. Pittman K. (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32: 760–767.
19. Iacovelli R. Cartenì G. Milella M. Berardi R. Di Lorenzo G. Verzoni E. (2014) Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. Can Urol Assoc J 8: E121–E125.
20. Inoki K. Guan K. (2006) Complexity of the TOR signaling network. Trends Cell Biol 16: 206–212.
21. Lee C. Marschner I. Simes R. Voysey M. Egleston B. Hudes G. (2012) Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 18: 3188–3196.
22. Maroto J. Hudes G. Dutcher J. Logan T. White C. Krygowski M. (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29: 1750–1756.
23. McDermott D. Regan M. Clark J. Flaherty L. Weiss G. Logan T. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141.
24. Motzer R. Hudes G. Curti B. McDermott D. Escudier B. Negrier S. (2007) Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25: 3958–3964.
25. Motzer R. Murphy B. Bacik J. Schwartz L. Nanus D. Mariani T. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18: 2972–2980.
26. NCCN (2015) Kidney cancer. NCCN Clinical Practice Guidelines in Oncology, Version 2.2015. Fort Washington, PA: National Comprehensive Cancer Network.
27. Negrier S. Escudier B. Lasset C. Douillard J. Savary J. Chevreau C. (1998) Recombinanthuman interleukin-2, recombinanthuman interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272–1278.
28. Oppe M. Rabin R. de Charro F. (2008) EQ-5D user guide, version 1.0. Rotterdam: EuroQol Group.
29. Patard J. Leray E. Rioux-Leclercq N. Cindolo L. Ficarra V. Zisman A. (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23: 2763–2771.
30. Procopio G. Verzoni E. De Braud F. (2014) Butterfly and renal cell cancer: out of chaos comes order. J Clin Oncol 32: 3083–3084.
31. Radice D. Redaeli A. (2005) Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. Pharmacoeconomics 23: 69–75.
32. Raymond E. Alexandre J. Faivre S. Vera K. Materman E. Boni J. (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22: 2336–2347.
33. Schmelzle T. Hall M. (2000) TOR, a central controller of cell growth. Cell 103: 253–262.
34. Sherrill B. Amonkar M. Stein S. Walker M. Geyer C. Cameron D. (2008) Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 99: 711–715.
35. Zbrozek A. Hudes G. Levy D. Strahs A. Berkenblit A. DeMarinis R. (2010) Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics 28: 577–5784.